Skip to main content
OpenTrials
Completed

NCT Number: NCT00140504

Preventing Adverse Drug Events With PatientSite

This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adverse Drug Event Chemically-Induced Disorders Drug-Related Side Effects and Adverse Reactions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

About this study

  • A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
  • Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
  • To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
  • This study will run for 12 months.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients >18
  • Patients that receive a new prescription
  • Proficient in spoken and written english

Exclusion criteria

Treatment and study plan

Medcheck message

Other

Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician

Primary outcomes

  1. To prevent adverse drug events with PatientSite.

    Time frame: 3 years

Secondary outcomes

  1. Improve patient satisfaction

    Time frame: 3 years

  2. better utilization of services

    Time frame: 3 years

  3. improve patient-clinician communication

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)
  • Beth Israel Deaconess Medical Center
  • Blue Cross Blue Shield

Registry information

Important dates

Study start
2003
Primary completion
2004
Study completion
2004
First posted
Sep 1, 2005
Registry last updated
Feb 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.